Table II:

Association between prenatal plasma PUFA and child atopic dermatitis (AD) outcomes at 4–6 years in dyads enrolled in CANDLE

Maternal plasma PUFA percentage (continuous)	Current AD		Location-specific AD		Ever AD
	Unadjusted OR [CI]†	Adjusted OR [CI]†,‡	Unadjusted OR [CI]†	Adjusted OR [CI]†,‡	Unadjusted OR [CI]†	Adjusted OR [CI]†,‡
Omega-3 (n-3)§	0.99 (0.82–1.20)	1.07 (0.86–1.32)	0.95 (0.78–1.16)	1.03 (0.82–1.28)	0.98 (0.84–1.14)	1.09 (0.92–1.30)
Omega-6 (n-6)§	1.24 (1.01–1.51)*	1.25 (1.01–1.54)*	1.27 (1.03–1.56)*	1.27 (1.02–1.59)*	1.19 (1.02–1.40)*	1.16 (0.98–1.37)
n-6:n-3	1.05 (0.86–1.27)	1.00 (0.81–1.24)	1.09 (0.89–1.33)	1.04 (0.83–1.30)	1.04 (0.89–1.21)	0.96 (0.80–1.14)

^†OR: Odds Ratio; CI: 95% Confidence Interval; ORs are estimated per interquartile range increase in respective PUFA value

^‡Adjusted for maternal age at enrollment, self-reported race, education level, smoking during pregnancy, pre-pregnancy BMI, atopic disease history, parity, route of delivery, and child sex

^§As percentage of total plasma fatty acids